Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Valeant Pharmaceuticals acquires DermaTech
Aliso Viejo, Calif. - Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, marketwatch reports.
Aliso Viejo, Calif.
- Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, for AU$19 million, marketwatch reports.
The transaction will expand Valeant’s specialty pharmaceutical portfolio through the acquisition of key products,according to the company.
Related Videos
Related Content
